Results 281 to 290 of about 3,105,782 (329)

Evaluation of HIV-1 reservoir levels as possible markers for virological failure during boosted darunavir monotherapy.

Journal of Antimicrobial Chemotherapy, 2019
BACKGROUND The gold standard for HIV-1 treatment is to administer triple antiretroviral therapy, but a shift to simplified regimens is being explored.
S. Rutsaert, W. De Spiegelaere, Laura De Clercq, L. Vandekerckhove   +3 more
semanticscholar   +1 more source

Tackling virological failure in HIV-infected children living in Africa

Expert Review of Anti-infective Therapy, 2015
Drug resistance in HIV-infected children is one of the main contributors to antiretroviral treatment (ART) failure, especially in developing countries. Sub-Saharan Africa has the largest burden of pediatric HIV infection in the world. Herein, we systematically review the current status of ART failure in HIV-infected African children.
Mohammad-Ali, Jenabian, Cecilia T, Costiniuk, Ralph-Sydney, Mboumba Bouassa, Linda, Chapdeleine Mekue Mouafo, Thomas V, Brogan, Laurent, Bélec   +5 more
openaire   +2 more sources

Prevalence and Factors Associated With Virological Treatment Failure Among Children and Adolescents on Antiretroviral Therapy Attending HIV/AIDS Care and Treatment Clinics in Dodoma Municipality, Central Tanzania.

Journal of the Pediatric Infectious Diseases Society, 2020
BACKGROUND As the World Health Organization (WHO) and its joint partners such as USAIDS target achieving 90% sustained virological suppression among children and adolescents living with Human Immunodeficience Virus (HIV)/AIDS, it is imperative to ...
Niyonziza Z Bitwale, D. Mnzava, Francisca D Kimaro, Theopista Jacob, B. Mpondo, Shakilu Jumanne   +5 more
semanticscholar   +1 more source

PROTEASE INHIBITOR RESISTANCE IN SOUTH AFRICAN CHILDREN WITH VIROLOGIC FAILURE

Pediatric Infectious Disease Journal, 2009
In South Africa, first-line antiretroviral therapy for children younger than 3 years of age combines a protease inhibitor (PI) with 2 nucleoside reverse transcription inhibitors. In our study, some pediatric patients received ritonavir (RTV) as single PI (RTV-sPI) and others ritonavir-boosted lopinavir (LPV/r), which has a higher resistance barrier. We
Van Zyl G.U., Van Der Merwe L., Claassen M., Cotton M.F., Rabie H., Prozesky H.W., Preiser W.   +6 more
openaire   +3 more sources

Cerebrospinal fluid response to structured treatment interruption after virological failure

AIDS, 2001
Structured antiretroviral treatment interruption (STI) has been advocated as a therapeutic strategy for HIV-1 infection. We report initial observations of cerebrospinal fluid (CSF) HIV-1 infection in five patients undergoing serial lumbar punctures (LPs) during STI undertaken following virological failure.In this prospective observational study we ...
R W, Price, E E, Paxinos, R M, Grant, B, Drews, A, Nilsson, R, Hoh, N S, Hellmann, C J, Petropoulos, S G, Deeks   +8 more
openaire   +2 more sources

Nirmatrelvir resistance - de novo E166V/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir/ritonavir monotherapy leading to clinical and virological treatment failure - a case report.

Clinical Infectious Diseases, 2023
N. Zuckerman, E. Bucris, Danielle Keidar-Friedman, Muriel Amsalem, Tal Brosh-Nissimov   +4 more
semanticscholar   +1 more source

Burden and Associated Factors of Virological Failure Among People Living with HIV in Sub-Saharan Africa: A Systematic Review and Meta-Analysis

Aids and Behavior, 2022
Chilot Desta Agegnehu, M. A. Techane, Abraham Tarekegn Mersha, Kendalem Asmare Atalell   +3 more
semanticscholar   +1 more source

Virological patterns of HCV patients with failure to interferon‐free regimens

Journal of Medical Virology, 2018
The study characterized the virological patterns and the resistance‐associated substitutions (RASs) in patients with failure to IFN‐free regimens enrolled in the real‐life setting. All 87 consecutive HCV patients with failed IFN‐free regimens, observed at the laboratory of the University of Campania, were enrolled.
Starace M, Minichini C, De Pascalis S, Macera M, Occhiello L, Messina V, Sangiovanni V, Adinolfi LE, Claar E, Precone D, Stornaiuolo G, Stanzione M, Ascione T, Caroprese M, Zampino R, Parrilli G, Gentile I, Brancaccio G, Iovinella V, Martini S, Masarone M, Fontanella L, Masiello A, Sagnelli E, Punzi R, Salomone Megna A, Santoro R, Gaeta GB, Coppola N., Stornaiuolo G, Zampino R. Parrilli G, Masarone M.   +31 more
openaire   +5 more sources

Does an Increase in Nevirapine Plasma Levels Cause Complete Virologic Suppression in Patients Experiencing Early Virologic Failure?

HIV Clinical Trials, 2002
Patients on two nucleoside analogs plus nevirapine (NVP) who show low-level plasma HIV RNA might have insufficient NVP plasma levels and therefore might benefit from an increase in NVP dosing.The dose of NVP was increased from 400 mg/day to 600 mg/day in 25 participants taking NVP-containing triple combinations for at least 3 months and experiencing a ...
Daniel González, de Requena, Marina, Núñez, Oscar, Gallego, Inmaculada, Jiménez-Nácher, Juan, González-Lahoz, Vincent, Soriano   +5 more
openaire   +2 more sources

Virologic Failure of High-Dose Raltegravir With Concomitant Rifampin

Infectious Diseases in Clinical Practice, 2017
Abstract Treating mycobacterial infections and HIV concurrently typically presents difficulties due to drug-to-drug interactions between rifampin and many antiretrovirals. We present a case of raltegravir failure during concomitant rifampin use, despite documented administration of recommended increased dose of raltegravir.
Misty M. Miller, Karen K. Kinney, Michelle D. Liedtke   +2 more
openaire   +1 more source